MarketPeel
Insider Trading Intelligence
Pricing
…
DB

David P. Bonita

IMA
DIRECTOR · IMAGENEBIO, INC. · CIK 0001572451
FILING MIX · LIFETIME76%/24%
BUYS
22
SELLS
7
TOTAL VALUE
$46.00M
COMPANIES
2
ACTIVE SINCE
Mar 2020
HOLDINGS NOW
53,600
AVG SELL PX
—
TRADE KIND
SHOWING 29 / 29
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 2 pending
Forward-return performance of every backtestable P/S trade by David P. Bonita, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+100.00%+5.28%-0.70%+5.97%+5.52%—
14d3+66.67%+1.33%+1.17%+0.17%+6.61%—
30d3+33.33%+3.24%+2.70%+0.54%-11.37%—
60d3+0.00%-28.67%+5.51%-34.18%-24.83%—
90d3+0.00%-49.31%+6.60%-55.91%-61.12%—
180d3+0.00%-50.34%+10.59%-60.93%-66.21%—
1y3(1 pending)+0.00%-55.40%+27.21%-82.61%-82.61%—
2y3(1 pending)+0.00%-87.69%+25.27%-112.97%-112.97%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
IMA · 15,600 shares · as of Jun 16, 2026
096,172192,345288,517384,6892026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 22 buys / 7 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
IMA
IMAGENEBIO, INC.
PURCHASEGRANT
Stock grant
15,600——15,600Jun 16, 2026Jun 18, 2026 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
38,000——38,000Jun 9, 2026Jun 10, 2026 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASE
1,689,189$4.44$7.50M11,808,945Apr 21, 2026Apr 23, 2026 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASE
1,126,126$4.44$5.00M1,126,126Apr 21, 2026Apr 23, 2026 ↗View →
IMA
IMAGENEBIO, INC.
PURCHASE
336,603——336,603Apr 14, 2026Apr 16, 2026 ↗View →
IMA
IMAGENEBIO, INC.
PURCHASE
384,689——384,689Apr 14, 2026Apr 16, 2026 ↗View →
IMA
IMAGENEBIO, INC.
PURCHASE
83,611$29.90$2.50M287,885Jul 25, 2025Jul 30, 2025 ↗View →
IMA
IMAGENEBIO, INC.
PURCHASE
379——379Jul 25, 2025Jul 30, 2025 ↗View →
IMA
IMAGENEBIO, INC.
SALE
17,520——0Jul 25, 2025Jul 30, 2025 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
38,000——38,000Jun 12, 2025Jun 13, 2025 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
23,500——23,500Jun 14, 2024Jun 18, 2024 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
23,500——23,500Jun 16, 2023Jun 21, 2023 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASE
869,565$5.75$5.00M10,119,756May 22, 2023May 24, 2023 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
34,300——34,300Jun 17, 2022Jun 22, 2022 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
23,344——23,344Jun 18, 2021Jun 22, 2021 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASE
41,700$60.00$2.50M5,596,886Jan 11, 2021Jan 12, 2021 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
SALE
619,850——0Sep 29, 2020Sep 30, 2020 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
SALE
413,234——0Sep 29, 2020Sep 30, 2020 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
SALE
2,945,458——0Sep 29, 2020Sep 30, 2020 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASE
8,332,779——9,250,191Sep 29, 2020Sep 30, 2020 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
SALE
4,418,186——0Sep 29, 2020Sep 30, 2020 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
SALE
3,294,743——0Sep 29, 2020Sep 30, 2020 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASE
5,555,186——5,555,186Sep 29, 2020Sep 30, 2020 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
SALE
2,196,494——0Sep 29, 2020Sep 30, 2020 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASE
710,500$19.00$13.50M917,412Sep 25, 2020Sep 30, 2020 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASE
526,300$19.00$10.00M526,300Sep 25, 2020Sep 30, 2020 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
46,688——46,688Sep 24, 2020Sep 30, 2020 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASE
1,033,084——1,033,084Aug 21, 2020Sep 30, 2020 ↗View →
PRLD
PRELUDE THERAPEUTICS INC
PURCHASE
3,681,822——7,363,644Mar 27, 2020Sep 30, 2020 ↗View →
Other insiders · IMA
Loading peer insiders…
About this filer
CIK 0001572451
ROLE
Director
PRIMARY
IMA
COMPANIES
2
ACTIVE SINCE
Mar 2020
MARKETPEEL · /INSIDER/0001572451DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback